Rutherford’s classification
diabetic
DISEASE
We used Rutherford’s classification as a numerical objective evaluation to determine the CLTI severity. We found a statistically significant decrease in Rutherford’s classification in the auto-BM-MNC and allo-WJ-MSC groups from the first month (Rutherford < 3), which persisted until 12 months after administrating the cell-based therapy, unlike the placebo group, whose participants increased their classification to a more advanced stage of the disease (Rutherford 6) (Fig. Severity Rutherford’s classification decreased in auto-BM-MNC and allo-WJ-MSC—treated diabetic patients with CTLI. Rutherford’s classification decreased in the auto-BM-MNC and allo-WJ-MSC groups starting from the first month (Rutherford < 3), which persisted until 12 months after cell-based therapy, unlike the placebo group, whose participants increased their classification to a more severe stage of the disease (Rutherford 6). Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (